On May 15, 2019, Brian Piper, the Chief Financial Officer and Secretary of Aevi Genomic Medicine, Inc., informed the Company that he would be resigning his employment with the Company, effective May 31, 2019. Michael McInaw, the Company's current Controller, will be appointed interim Chief Financial Officer effective June 1, 2019. Mr. McInaw, 32, joined the Company in July 2016 as a senior accountant, before serving as manager of accounting and finance, and most recently serving as the Company's Controller since March 2018.

Prior to joining the Company, Mr. McInaw served, most recently as accounting supervisor, at Telerx LLC, a subsidiary of Merck & Co. from 2015 to 2016, and in various accounting roles at Quest Diagnostics, Inc. from 2009 to 2015. Mr. McInaw is a Certified Management Accountant and Certified Public Accountant and received both a B.S. in finance and M.B.A. with concentrations in accounting and finance from St.

Joseph's University.